RxDoctor Payments Data

Christopher Shanklin, MD

Family Medicine · Lubbock, TXNPI 1154513182

Payments from drug & device makers

$6,373in general payments, 2019–2025

Across 345 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$817
  • Amgen$727
  • Lilly USA, LLC$571
  • Pfizer$357
  • Boehringer Ingelheim$327
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,364100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,373 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$244,355
Medicare patients
528
Services billed
4,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide123$144,989
Synjardy XrEmpagliflozin/Metformin Hcl61$56,150
FarxigaDapagliflozin Propanediol70$55,378
JardianceEmpagliflozin42$48,023
Janumet XrSitagliptin Phos/Metformin Hcl12$17,400
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,542
GlyxambiEmpagliflozin/Linagliptin12$14,365
MounjaroTirzepatide12$12,255
EliquisApixaban11$8,121
Levothyroxine Sodium336$3,393
Rosuvastatin Calcium329$3,118
Pantoprazole Sodium193$2,251
Raloxifene Hcl51$2,084
Gabapentin106$1,984
Atorvastatin Calcium253$1,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$817$145,906136 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Glyxambi$327$118,538115 claims
AstraZenecaFarxiga$266$55,37870 claims
MerckJanumet Xr$25$17,40012 claims
GSKTrelegy Ellipta$193$16,54220 claims
Lilly USA, LLCMounjaro$571$12,25512 claims
PfizerEliquis$357$8,12111 claims
AbbVieArmour Thyroid$1,061$1,89329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →